Slingshot members are tracking this event:
New Phase 1 Clinical Data Evaluating Amgen's (AMGN) AMG 510 In Patients With Solid Tumors Presented At ESMO 2019
Do you think this event is important to the companies below? How will it affect their stock price?
|Impact on Stocks
The study enrolled 76 patients with KRAS G12C-mutant solid tumors. Data being presented at ESMO include a subset of 55 evaluable patients as of the July 2019 data cutoff, including CRC, appendiceal cancer and NSCLC patients from the Phase 1 study. Of the 55 patients, 29 had CRC. Twelve patients with CRC received the target dose of 960 mg once daily and 10 remain on treatment. One patient in this dose cohort experienced a partial response and 10 had stable disease for a disease control rate of 92%. Thirteen of the evaluable patients with NSCLC received 960 mg, of which seven (54%) achieved a partial response at one or more timepoints and six (46%) achieved stable disease, for a disease control rate of 100%. Data across dosing cohorts also showed tumor responses in two evaluable patients with appendiceal cancer with one partial response and one experiencing stable disease.
Slingshot Insights Explained
Sep 27, 2019
Don’t see a project related to the catalyst you care about?
Related Keywords Amg 510, Esmo Annual Congress